Seven patients with 24 local or distant metastatic renal cell carcinoma (RCC) lesions underwent 89Zr-Atezolizumab PET/CT. Subjects were scanned on a Biograph mCT Flow PET/CT system (Siemens Medical Solutions, Germany). Images were reconstructed using the vendor's ordered subset expectation ...
et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 24, 1852–1858 (2018). https://doi.org/10.1038/s41591-018-0255-8 Download citation Received09 March 2018 Accepted10 September 2018 Published26 November 2018 Issue ...
在这里,我们介绍了第一次人体研究的初步结果,以评估用锆- 89标记的atezolizumab (抗PD - L1 )成像的可行性,包括生物分布,然后测试其预测对PD - L1阻断反应的潜力( ClinicalTrials.gov标识符NCT 02453984和NCT 02478099 )。在阿替唑单抗治疗开始前,我们对22名患者进行了三种肿瘤类型的成像。PET信号是示踪剂暴露和...
Zr89-Atezo示踪剂的摄入可能会成为评估atezolizumab临床疗效,包括PFS和OS的较强预测标志,未来需要大样本研究并结合其他临床数据来进一步确认。
[89Zr]-AtezolizumabPDXdosimetryMDA-MB-231Triple-negative breast cancer is characterized by a lack of targetable treatment receptors and current standard of care options, such as radiation therapy and chemotherapy, are associated with acute patient toxicity. Noninvasive imaging of PD-L1, ...
435TiP Molecular imaging of programmed death ligand 1 (PD-L1) expression with [89Zr]Zr-atezolizumab positron emission tomography/computed tomography (PET/CT) in patients with metastatic triple negative breast cancer (mTNBC): The MIMIR-study
PD-L1 detection using 89Zr-atezolizumab immuno-PET in renal cell carcinoma tumorgrafts from a patient with favorable nivolumab responseKidney cancer, Renal cancer, Immuno-PET, PD-L1, PD-1, PDX, Patient-derived xenograft, IO, Immunotherapy, Immune checkpoint inhibitors, Predictive biomarkers, SABR,...